[{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$45.0 million","newsHeadline":"Ionis Enters Exclusive Licensing Agreement with Bicycle Therapeutics Aimed at Further Advancing LICA Technology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Bicycle Therapeutics"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evox Therapeutics Enters into Agreement to Advance Next Generation Exosome-Delivered AAV Gene Therapy for the Treatment of Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Evox Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The collaboration aims to work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving treatments for heart disease.
Lead Product(s):
Exosome-encapsulated AAV-based Gene Therapy
Under terms of the agreement, Ionis obtained an exclusive license to Bicycle's technology covering the entire class of transferrin receptor 1 Bicycles for use in targeted delivery of oligonucleotide drugs.